* The 13th Aging Research & Drug Discovery (ARDD) Meeting will take place October 1-3, 2026.
* The event location is the David Rubenstein Treehouse at Harvard University.
* Insilico Medicine organizes the conference and anchors it as a Tier 1 sponsor alongside Eli Lilly.
* The meeting serves as a nexus for longevity biotechnology, connecting basic science, clinical research, big pharma, and institutional investors.
* Past events included ARDD 2025 in Copenhagen.
* Pharmaceutical development targets fibrosis, immunology, CNS, cardiometabolic diseases, anti-muscle wasting, and cellular rejuvenation.
* The program includes tracks: Clinical Development Day and the Longevity Medicine Track (October 1), AI in Drug Discovery Track (October 2), and Future Technology Track (October 3).
* Global chairs include Vadim Gladyshev and Jesse Poganik (Harvard Medical School), Alex Zhavoronkov (Insilico Medicine), Morten Scheibye-Knudsen and Daniela Bakula (The University of Copenhagen), Evelyne Bischof (Sheba Longevity Center), and Maximilian Unfried (National University of Singapore).
* The McKinsey Health Institute joins as the Sole Knowledge Partner.
* Tier 1 sponsors include Eli Lilly and Insilico Medicine, with additional Tier 3 sponsors listed.

The 13th Aging Research & Drug Discovery (ARDD) Meeting will occur from October 1-3, 2026, at the David Rubenstein Treehouse at Harvard University. The event is organized by Insilico Medicine and is co-anchored as a Tier 1 sponsor alongside Eli Lilly. This conference serves as a nexus for longevity biotechnology, connecting basic science, clinical research, big pharma, and institutional investors.
The program emphasizes the transition of longevity science into mainstream medicine, reflecting the field's evolution. The event builds on previous momentum, with prior events featuring discussions on GLP-1 receptor agonists in Nature Biotechnology. Current pharmaceutical development is focusing on areas such as fibrosis, immunology, CNS, cardiometabolic diseases, anti-muscle wasting, and cellular rejuvenation.
The program structure includes specialized daily tracks: Clinical Development and Longevity Medicine, AI in Drug Discovery, and Future Technology. The event will feature high-profile receptions with confirmed speakers from executive leaders of ten top pharmaceutical companies. Global chairs representing major academic institutions will steer the meeting, and the McKinsey Health Institute is serving as the Sole Knowledge Partner. Sponsorship involves multiple tiers, including partners like Eli Lilly and Insilico Medicine at Tier 1, and various other biotechnology and financial entities.

The narrative positions aging research not merely as an academic pursuit but as a rapidly maturing, multi-billion-dollar commercial enterprise integrating deeply into mainstream medicine. The shift from theoretical concepts to therapeutic pipelines reflects a critical inflection point where fundamental science translates directly into pharmaceutical and investment action. The centralization of this ecosystem at Harvard and Boston underscores the gravity of longevity science’s institutional acceptance.
The structure of the conference itself—segmenting the focus across clinical development, AI, and future technology—suggests a strategic imperative: moving the field from pure discovery to actionable translation. The involvement of major pharmaceutical giants and top academic chairs indicates that the field has achieved sufficient weight to demand cross-sector governance. However, the emphasis on high-profile networking and sponsorship alongside scientific tracks raises questions about the balance between pure research integrity and commercial momentum in setting the agenda for a field often driven by long-term societal concerns.
The layered sponsorship structure reveals a complex system of influence where capital (Tier 4 and Tier 5 sponsors) is directly integrated with institutional leadership. This dynamic suggests that the "center" of longevity innovation is shaped not only by scientific consensus but also by the financial architecture supporting it. The core tension lies in whether this concentration of power accelerates beneficial medical translation or risks prioritizing market-driven outcomes over broader public health equity, particularly given the focus on specific disease targets like CNS and cardiometabolic issues. What assumptions underpin the belief that this convergence inherently serves the goal of longevity rather than purely maximizing invested interests?